Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new ...

DREAMS-2: A Phase 3 study comparing mazdutide and dulaglutide in Chinese T2D patients with inadequate glycemic control on ...

Isaralgagene civaparvovec is a “potential best-in-class gene therapy for Fabry disease,” according to analysts at H.C.

See-sawing global tariffs, a US regulator in flux and a possible end to US drug price premia are not, apparently, enough to ...